Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials

医学 皮质类固醇 哮喘 恶化 安慰剂 内科学 嗜酸性粒细胞 强的松 胃肠病学 麻醉 病理 替代医学
作者
Jonathan A. Bernstein,J. Christian Virchow,Kevin R. Murphy,Jorge Máspero,Joshua Jacobs,Yochai Adir,Marc Humbert,Mario Castro,Douglas Marsteller,Jennifer McElhattan,Lisa Hickey,Margaret Garin,Rebecca Vanlandingham,Guy Brusselle
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (5): 461-474 被引量:83
标识
DOI:10.1016/s2213-2600(19)30372-8
摘要

Reslizumab 3 mg/kg administered intravenously is approved for the treatment of severe eosinophilic asthma. We assessed the safety and efficacy of subcutaneous reslizumab 110 mg in two trials in patients with uncontrolled severe asthma and increased blood eosinophils. The aim was to establish whether subcutaneous reslizumab 110 mg can reduce exacerbation rates in these patients (study 1) or reduce maintenance oral corticosteroid dose in patients with corticosteroid-dependent asthma (study 2).Both studies were randomised, double-blind, placebo-controlled, phase 3 studies. Entry criteria for study 1 were uncontrolled severe asthma, two or more asthma exacerbations in the previous year, a blood eosinophil count of 300 cells per μL or more (including no more than 30% patients with an eosinophil count <400 cells/μL), and at least a medium dose of inhaled corticosteroids with one or more additional asthma controllers. Patients in study 2 had severe asthma, a blood eosinophil count of 300 cells per μL or more, daily maintenance oral corticosteroid (prednisone 5-40 mg, or equivalent), and high-dose inhaled corticosteroids plus another controller. Patients were randomly assigned (1:1) to subcutaneous reslizumab (110 mg) or placebo once every 4 weeks for 52 weeks in study 1 and 24 weeks in study 2. Patients and investigators were masked to treatment assignment. Primary efficacy outcomes were frequency of exacerbations during 52 weeks in study 1 and categorised percentage reduction in daily oral corticosteroid dose from baseline to weeks 20-24 in study 2. Primary efficacy analyses were by intention to treat, and safety analyses included all patients who received at least one dose of study treatment. These studies are registered with ClinicalTrials.gov, NCT02452190 (study 1) and NCT02501629 (study 2).Between Aug 12, 2015, and Jan 31, 2018, 468 patients in study 1 were randomly assigned to placebo (n=232) or subcutaneous reslizumab (n=236), and 177 in study 2 to placebo (n=89) or subcutaneous reslizumab (n=88). In study 1, we found no significant difference in the exacerbation rate between reslizumab and placebo in the intention-to-treat population (rate ratio 0·79, 95% CI 0·56-1·12; p=0·19). Subcutaneous reslizumab reduced exacerbation frequency compared with placebo in the subgroup of patients with blood eosinophil counts of 400 cells per μL or more (0·64, 95% CI 0·43-0·95). Greater reductions in annual exacerbation risk (p=0·0035) and longer time to first exacerbation were observed for patients with higher trough serum reslizumab concentrations. In study 2, we found no difference between placebo and fixed-dose subcutaneous reslizumab in categorised percentage reduction in daily oral corticosteroid dose (odds ratio for a lower category of oral corticosteroid use in the reslizumab group vs the placebo group, 1·23, 95% CI 0·70-2·16; p=0·47). The frequency of adverse events and serious adverse events with reslizumab were similar to those with placebo in both studies.Fixed-dose (110 mg) subcutaneous reslizumab was not effective in reducing exacerbation frequency in patients with uncontrolled asthma and increased blood eosinophils (≥300 cells/μL), or in reducing the daily maintenance oral corticosteroid dose in patients with oral corticosteroid-dependent severe eosinophilic asthma. Higher exposures than those observed with 110 mg subcutaneous reslizumab are required to achieve maximal efficacy.Teva Branded Pharmaceutical Products R&D.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
孙亦沈完成签到,获得积分10
1秒前
樊凡完成签到,获得积分10
1秒前
852的应助被xl采纳,获得10
1秒前
1秒前
2秒前
善良静竹完成签到 ,获得积分10
2秒前
2秒前
toki完成签到,获得积分10
2秒前
Guo举报kkk的求助涉嫌违规
3秒前
3秒前
辋川完成签到,获得积分10
4秒前
min完成签到,获得积分10
4秒前
12发布了新的文献求助10
4秒前
周星宇完成签到,获得积分10
5秒前
凉介完成签到,获得积分10
6秒前
无误发布了新的文献求助10
6秒前
7秒前
7秒前
WzJCW完成签到,获得积分20
7秒前
梦寐寤寐发布了新的文献求助10
7秒前
8秒前
王12完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
11秒前
skip发布了新的文献求助10
11秒前
11秒前
Ican发布了新的文献求助10
11秒前
11秒前
通过发布了新的文献求助10
12秒前
不安的问雁完成签到,获得积分20
12秒前
拜拜拜仁完成签到,获得积分10
12秒前
晨晨的应助被WSND采纳,获得50
14秒前
15秒前
16秒前
17秒前
orange发布了新的文献求助10
17秒前
17秒前
chris chen完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579325
关于积分的说明 21864493
捐赠科研通 7792494
什么是DOI,文献DOI怎么找? 3437087
关于科研通互助平台的介绍 2560652
邀请新用户注册赠送积分活动 2483937